{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:03:18Z","timestamp":1793030598983,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacadv.2026.102744","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:18:06Z","timestamp":1777609086000},"page":"102744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P1","title":["Lipoprotein(a) and Women\u2019s Cardiovascular Health"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D.","family":"Michos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Saucier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacadv.2026.102744_bib1","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jacadv.2026.102744_bib2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jacc.2020.03.060","article-title":"Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review","volume":"75","author":"Cho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102744_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"issue":"10155","key":"10.1016\/j.jacadv.2026.102744_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib5","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.102744_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","author":"Marcovina","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeae064","article-title":"Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk","volume":"4","author":"Harb","year":"2024","journal-title":"Eur Heart J Open"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102744_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/clinchem\/45.7.1039","article-title":"Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study","volume":"45","author":"Seman","year":"1999","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0026-0495(86)90150-2","article-title":"Fluctuations of plasma lipoprotein-a concentrations during pregnancy and post partum","volume":"35","author":"Zechner","year":"1986","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(99)00296-8","article-title":"Lipoprotein (a) levels in normal pregnancy and in pregnancy complicated with pre-eclampsia","volume":"148","author":"Sattar","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","article-title":"Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events","volume":"52","author":"Suk Danik","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102744_bib14","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA"},{"issue":"10459","key":"10.1016\/j.jacadv.2026.102744_bib15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jjcc.2012.09.009","article-title":"The current status of lipoprotein (a) in pregnancy: a literature review","volume":"61","author":"Fanshawe","year":"2013","journal-title":"J Cardiol"},{"issue":"39","key":"10.1016\/j.jacadv.2026.102744_bib17","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1093\/eurheartj\/ehad472","article-title":"Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society","volume":"44","author":"Roeters van Lennep","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102744_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.maturitas.2022.09.012","article-title":"The effect of menopause on lipoprotein (a) concentrations: a systematic review and meta-analysis","volume":"167","author":"Anagnostis","year":"2023","journal-title":"Maturitas"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102744_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70012","article-title":"Is there a need for sex-tailored lipoprotein(a) cut-off values for coronary artery disease risk stratification?","volume":"47","author":"Yurtseven","year":"2024","journal-title":"Clin Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41569-022-00797-4","article-title":"Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes","volume":"20","author":"Regitz-Zagrosek","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102744_bib21","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1007\/s12325-019-01107-0","article-title":"Gender disparities in health resource utilization in patients with atherosclerotic cardiovascular disease: a retrospective cross-sectional study","volume":"36","author":"Shen","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacadv.2026.102744_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117269","article-title":"Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women","volume":"384","author":"Rajendran","year":"2023","journal-title":"Atherosclerosis"},{"issue":"10292","key":"10.1016\/j.jacadv.2026.102744_bib23","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102744_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102744_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11936-020-00869-z","article-title":"Disparities in cardiovascular care and outcomes for women from racial\/ethnic minority backgrounds","volume":"22","author":"Balla","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2026.102744_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.017","article-title":"Sex differences in LDL-C control in a primary care population: the PORTRAIT-DYS study","volume":"384","author":"Gavina","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2026.102744_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.phrs.2017.01.025","article-title":"Gender differences in cardiovascular prophylaxis: focus on antiplatelet treatment","volume":"119","author":"Di Giosia","year":"2017","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102744_bib28","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102744_bib29","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacadv.2026.102744_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102744_bib31","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib32","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"39","key":"10.1016\/j.jacadv.2026.102744_bib33","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102744_bib34","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102744_bib35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/01.ATV.16.3.471","article-title":"Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) study","volume":"16","author":"Schreiner","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33549\/physiolres.930511","article-title":"Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease","volume":"53","author":"Frohlich","year":"2004","journal-title":"Physiol Res"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102744_bib38","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102744_bib39","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.CIR.95.2.329","article-title":"Lipoprotein(a) as a determinant of coronary heart disease in young women","volume":"95","author":"Orth-Gom\u00e9r","year":"1997","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102744_bib41","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.296.11.1363","article-title":"Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women","volume":"296","author":"Suk Danik","year":"2006","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.jacadv.2026.102744_bib42","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/eurheartj\/ehi222","article-title":"Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?","volume":"26","author":"Shai","year":"2005","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and cardiovascular risk prediction among women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102744_bib44","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa001066","article-title":"Lp(a) lipoprotein, vascular disease, and mortality in the elderly","volume":"349","author":"Ariyo","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib45","first-page":"295","article-title":"Determination of lipoprotein(a): evaluation of three methods","volume":"31","author":"M\u00e4rz","year":"1993","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14647273.2021.1919764","article-title":"Role of endometriosis in defining cardiovascular risk: a gender medicine approach for women\u2019s health","volume":"25","author":"Cirillo","year":"2022","journal-title":"Hum Fertil (Camb)"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40292-023-00585-2","article-title":"Plasma lipoprotein(a) levels in polycystic ovary syndrome: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.jacadv.2026.102744_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117270","article-title":"Sex differences in lipids: a life course approach","volume":"384","author":"Holven","year":"2023","journal-title":"Atherosclerosis"},{"issue":"7627","key":"10.1016\/j.jacadv.2026.102744_bib49","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/bmj.39366.416817.BE","article-title":"Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study","volume":"335","author":"Magnussen","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/01443615.2019.1603214","article-title":"Correlation of elevated levels of lipoprotein(a), high-density lipoprotein and low-density lipoprotein with severity of preeclampsia: a prospective longitudinal study","volume":"40","author":"Konrad","year":"2020","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.jacadv.2026.102744_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100885","article-title":"Lipoprotein(a) throughout life in women","volume":"20","author":"Corral","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/jmf.14.2.91.95","article-title":"Changes of plasma lipoprotein(a) during and after normal pregnancy in Caucasians","volume":"14","author":"Manten","year":"2003","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.mehy.2004.04.026","article-title":"The role of lipoprotein (a) in pregnancies complicated by pre-eclampsia","volume":"64","author":"Manten","year":"2005","journal-title":"Med Hypotheses"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib54","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.fertnstert.2016.01.014","article-title":"Searching for a common mechanism for placenta-mediated pregnancy complications and cardiovascular disease: role of lipoprotein(a)","volume":"105","author":"Romagnuolo","year":"2016","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102744_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22568","article-title":"Epidemiological analysis of maternal lipid levels during the second trimester in pregnancy and the risk of adverse pregnancy outcome adjusted by pregnancy BMI","volume":"32","author":"Yue","year":"2018","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib56","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/ajh\/hpx020","article-title":"Retinol-binding protein 4 and lipids prospectively measured during early to mid-pregnancy in relation to preeclampsia and preterm birth risk","volume":"30","author":"Mendola","year":"2017","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib57","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.12669\/pjms.296.3863","article-title":"Abnormal lipid levels as a risk factor of eclampsia, study conducted in tertiary care hospitals of Khyber Pakhtunkhwa province - Pakistan","volume":"29","author":"Nazli","year":"2013","journal-title":"Pak J Med Sci"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3329\/bmrcb.v36i3.7289","article-title":"Lipoprotein (a) level in pre-eclampsia patients","volume":"36","author":"Parvin","year":"2010","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/09513590.2018.1532990","article-title":"Paraoxonase 1 (PON1) Q192R and L55M polymorphisms, lipid profile, lipid peroxidation and lipoprotein-a levels in Turkish patients with pregnancy-related disorders","volume":"35","author":"Aydemir","year":"2019","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib60","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1177\/147323001103900430","article-title":"Serum levels of lipids, lipoproteins and paraoxonase activity in pre-eclampsia","volume":"39","author":"Demir","year":"2011","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0020-7292(98)00007-1","article-title":"Antiphospholipid antibodies and lipoprotein (a) in women with recurrent fetal loss","volume":"61","author":"Szczepa\u0144ski","year":"1998","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1160\/TH04-08-0519","article-title":"Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage. Results of a multicentre case-control study","volume":"93","author":"Krause","year":"2005","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib63","first-page":"10","article-title":"Lipoprotein(a) concentrations in women with a history of severe preeclampsia--a case control study","volume":"82","author":"van Pampus","year":"1999","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib64","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/1570161116666181002145340","article-title":"Cardiovascular risk in perimenopausal women","volume":"17","author":"Stevenson","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib65","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/CIRCULATIONAHA.120.051775","article-title":"Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women","volume":"143","author":"Honigberg","year":"2021","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102744_bib66","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jacadv.2026.102744_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102744_bib68","doi-asserted-by":"crossref","first-page":"15569","DOI":"10.1074\/jbc.274.22.15569","article-title":"Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element","volume":"274","author":"Boffelli","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib69","first-page":"255","article-title":"Effect of serum lipoprotein (a) [Lp(a)] in menopausal women","volume":"25","author":"Bhakta","year":"2016","journal-title":"Mymensingh Med J"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archinte.1996.00440050046005","article-title":"Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy","volume":"156","author":"Kim","year":"1996","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib71","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0029-7844(96)00349-3","article-title":"Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy","volume":"88","author":"Bruschi","year":"1996","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13697139809080679","article-title":"Acute effects of a surgical menopause on serum concentrations of lipoprotein(a)","volume":"1","author":"Cheung","year":"1998","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib73","first-page":"81","article-title":"Beneficial effects of low doses of ethinyl-estradiol on the lipid profile in postmenopausal women","volume":"28","author":"Minozzi","year":"2001","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2015.06.056","article-title":"Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients","volume":"242","author":"Kotani","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib75","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/07853899509031958","article-title":"Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors","volume":"27","author":"Porkka","year":"1995","journal-title":"Ann Med"},{"key":"10.1016\/j.jacadv.2026.102744_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.maturitas.2017.02.009","article-title":"The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis","volume":"99","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"issue":"16","key":"10.1016\/j.jacadv.2026.102744_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030105","article-title":"Associations of oral contraceptive use with cardiovascular disease and all cause death: evidence from the UK Biobank Cohort Study","volume":"12","author":"Dou","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102744_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03632.x","article-title":"Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses","volume":"72","author":"Elamin","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib79","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.94.6.1263","article-title":"Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women \u226555 years of age","volume":"94","author":"Sunayama","year":"1996","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/jwh.2019.7773","article-title":"Lipoprotein(a) is associated with the presence and severity of new-onset coronary artery disease in postmenopausal women","volume":"29","author":"Yan","year":"2020","journal-title":"J Womens Health (Larchmt)"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102744_bib81","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamacardio.2022.0716","article-title":"Lipoprotein(a), menopausal hormone therapy, and risk of coronary heart disease in postmenopausal individuals","volume":"7","author":"Honigberg","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102744_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"18","key":"10.1016\/j.jacadv.2026.102744_bib83","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.jacadv.2026.102744_bib84","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.102744_bib85","author":"Alebna"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacl.2025.02.010","article-title":"Interlaboratory comparison of serum lipoprotein(a) analytical results across clinical assays\u2014Steps toward standardization","volume":"19","author":"Lyle","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102744_bib87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/00045632231210682","article-title":"The current status of lipoprotein (a) measurement in clinical biochemistry laboratories in the UK: results of a 2021 national survey","volume":"61","author":"Ansari","year":"2024","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102744_bib88","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11883-024-01192-9","article-title":"Novel therapies for lipoprotein(a): update in cardiovascular risk estimation and treatment","volume":"26","author":"Wulff","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacadv.2026.102744_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102744_bib90","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jacc.2025.07.014","article-title":"Very high prevalence of nonoptimally controlled traditional risk factors at the onset of cardiovascular disease","volume":"86","author":"Lee","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102744_bib91","article-title":"Gender matters: a multidimensional approach to optimizing cardiovascular health in women","volume":"16","author":"Sinha","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jacadv.2026.102744_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1315503","article-title":"Multidisciplinary management of cardiovascular disease in women: delphi consensus","volume":"11","author":"Gamez","year":"2024","journal-title":"Front Cardiovasc Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:51:38Z","timestamp":1789631498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26001651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772963X26001651"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102744","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and Women\u2019s Cardiovascular Health","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102744"}}